Last reviewed · How we verify
NCT04808713: RESILIENT
RESILIENT - An Online Multidimensional Treatment to Promote Resilience After a Disaster: Randomized Controlled Trial Protocol
NA trial testing Treatment in Post Traumatic Stress Disorder in 136 participants. Completed in 31 May 2019.
31 May 2019
Quick facts
| Lead sponsor | Laval University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 136 |
| Start date | 9 May 2017 |
| Primary completion | 31 May 2019 |
| Estimated completion | 31 May 2019 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Treatment — full drug profile →
Conditions studied
- Post Traumatic Stress Disorder — all drugs for Post Traumatic Stress Disorder →
- Insomnia — all drugs for Insomnia →
- Depression — all drugs for Depression →
Sponsor
Laval University
Who can join
Adults 18 to 120, any sex, with Post Traumatic Stress Disorder or Insomnia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Background. The wildfires on May 1, 2016 in Fort McMurray, Alberta (Canada), destroyed approximately 2,400 homes and buildings and led to massive displacement of approximately 88,000 people. Many individuals faced direct or potential threat to their life or health, or significant losses, and many months later, families were still living through ongoing adversity and uncertainty as they adapted to new or temporary homes, schools and workplaces. Alberta Health Services estimated in August 2016 that mental health staff in the city had received 20,000 referrals since May, compared to 1,200 referrals each year. Objectives. The overarching aim of this project is to understand the needs of the Fort McMurray population in terms of mental health and to widely disseminate evidence-based tools to promote resilience. More specifically, we will assess the efficacy of an online self-help intervention targeting post-traumatic resilience on specific symptoms (post-traumatic stress disorder \[PTSD\], insomnia, depression). Method. 1,510 phone surveys have been conducted in May-July 2017 to assess the prevalence of PTSD, insomnia and depression in the evacuees from the Fort McMurray wildfires (T0). After the survey, 697 participants expressed interest to participate in the longitudinal arm of the study, which will include four in-depth assessments with online questionnaires (T1 to T4) and a diagnostic interview (T1 only). A period of six months will separate all four times of assessment. Participants with post-traumatic stress symptoms (expected n = 150) will be randomised either to the treatment condition (n = 75) or to a waitlist control condition (n = 75) after completion of T2. Data Analyses. Primary outcomes will be post-traumatic, depressive and insomnia symptom severity, measured with validated self-report questionnaires. Secondary outcomes will include cognitive, behavioural and social indicators, as well as general mental health and post-traumatic growth. Several probable moderators of treatment will be examined, including sociodemographic characteristics, level of exposure, and continuing stressors. Foreseen Impacts. If found effective in reducing symptoms, the results of this study have the potential to impact positively the Fort McMurray community. Indeed, a direct and concrete deliverable of this research project will be to provide an extended (at least two years) and free access to the online intervention specifically tailored to this population's needs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04808713
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Treatment
Trials testing the same drug.
- NCT07322211 — A Study to Evaluate the Clinical Performance and Safety of UNICON Silicone Hydrogel Daily Disposable Soft Contact Lenses · NA · recruiting
- NCT07339553 — Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Ep · Phase 2 · not yet recruiting
- NCT07239622 — Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Ce · Phase 2 · not yet recruiting
- NCT06935240 — Investigation of Effects of Electrical Stimulation in Women With Vaginal Laxity · NA · recruiting
- NCT07176234 — The LEADS Trial (Linking Exericise for Advancing Daily Stress Management) · NA · recruiting
Other recruiting trials for Post Traumatic Stress Disorder
Currently open trials in the same condition.
- NCT07485231 — Nitric Oxide (NO) and Endothelial Dysfunction in Women With PTSD · NA · recruiting
- NCT07316088 — Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms · Phase 2 · recruiting
- NCT07227337 — Being Safe, Healthy, And Positively Empowered (BSHAPE) Intervention Study · NA · recruiting
- NCT06988787 — Multifaceted Intervention to Restore Resilience and Overcome Risk · NA · recruiting
- NCT06740487 — Advanced Wireless Augmented Reality-Enhanced Exposure Therapy for Posttraumatic Stress Disorder · NA · recruiting
Other Laval University trials
Trials by the same sponsor.
- NCT07491887 — Identification of Objective Metabolomics-based Biomarkers of Yogurt Consumption · NA · not yet recruiting
- NCT07366827 — Effectiveness of Motorised Lumbar Support for Non-specific Low Back Pain · NA · not yet recruiting
- NCT07317973 — A Study About Patient Decision Aids Designed to Help Parents and Guardians in Canada Make Evidence-informed, Values-cong · NA · not yet recruiting
- NCT07293312 — Optimizing the Use of Virtual Reality in Rehabilitation for Individuals With Persistent Shoulder Pain · NA · not yet recruiting
- NCT07201870 — Digital Preparation for Bariatric Surgery: Feasability Pilot Trial · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04808713 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Laval University
- Last refreshed: 13 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04808713.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing